You are here: Industry Insights > PAH

News List

Uptravi (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH) drugs
August 02, 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the FDA has approved Uptravi (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO
Janssen's UPTRAVI IV FDA-Approved for PAH contractpharma
August 02, 2021
New therapeutic option allows patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy.
Acceleron gets EC orphan designation for sotatercept to treat PAH pharmaceutical-business-review
December 17, 2020
Acceleron Pharma has secured orphan designation from the European Commission (EC) for its sotatercept to treat patients with pulmonary arterial hypertension (PAH).
Gmax BioPharm looking to enter competitive PAH market with early stage drug GMA301 expresspharma
November 27, 2020
Gmax BioPharm’s phase Ib clinical study is looking to enroll 36 patients with PAH, ages 18–75 years, to take part in a 22-week trial.
Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients pharmaceutical-business-review
September 23, 2020
Bayer said that the phase 4 REPLACE trial evaluating Adempas (riociguat) in intermediate-risk adult patients with pulmonary arterial hypertension (PAH) has met its primary endpoint.
FDA grants Orphan Drug Designation to sotatercept europeanpharmaceuticalreview
September 16, 2019
Orphan Drug Designation has been given to sotatercept for the treatment of patients with pulmonary arterial hypertension.
United Therapeutics scraps development of esuberaprost after late-stage study failure in PAH firstwordpharma
April 09, 2019
United Therapeutics on Monday announced that it will end development of esuberaprost for the treatment of pulmonary ……
Inhaled dry powder formulation of treprostinil works well in PAH patients europeanpharmaceuticalreview
January 16, 2019
A formulation of treprostinil as an inhaled dry powder has proven to be safe and effective, as reported in the safety analysis of a Phase III trial…
United Therapeutics buys Arena's hypertension drug ralinepag in deal worth $1.2 billion pharmafile
November 19, 2018
US pharma firm United Therapeutics has agreed to by Arena Pharmaceuticals experimental pulmonary arterial hypertension (PAH) drug ralinepag in a deal worth up to more than $1.2 billion.
PAH patients in England denied access to Actelion’s Uptravi on NHS pharmatimes
July 16, 2018
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.

Previous page 1 2 Next page